Molecular and Cellular Analysis of Lipogems-Processed Lipoaspirates for Evaluating the Efficacy of Treatments in Regenerative Medicine.
Al Sammarraie SHA., Alessio N., Aprile D., Castiglioni B., Squillaro T., Bosetti M.
Laboratory Study, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Stem Cell Rev Rep (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41964877
- PMCID
- PMC13241425
- DOI
- 10.1007/s12015-026-11094-9
Abstract (original English)
Autologous adipose tissue is a readily available source of mesenchymal stromal cells (MSCs) for regenerative applications. Here, human lipoaspirates from eight donors processed with the Lipogems system were characterized by flow cytometry (MSC/pericyte markers and inflammatory markers), immunocytochemistry (NANOG, OCT3/4, SOX2), and functional assays assessing proliferation, senescence, apoptosis, multilineage differentiation, IDO activity, and ROS levels. Lipogems-derived cultures fulfilled MSC immunophenotypic criteria while showing marked inter-donor variability in MSC/pericyte proportions, stemness-marker expression, differentiation bias, inflammatory profile, and oxidative status. In contrast, senescence and apoptosis were comparable across samples. Clinical evaluation, based on surgeon-assessed outcomes after autologous treatment, scored on a 1–10 scale, was consistently high across donors (7–10). Overall, Lipogems-processed lipoaspirates harbor a heterogeneous but functionally competent stromal compartment; these data support a sample-specific quality framework (composition, differentiation tendency, inflammation/ROS, IDO responsiveness) to improve reproducibility and optimization of regenerative protocols.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.